C4 Therapeutics Inc. (NASDAQ: CCCC) is considered one of the best biotech penny stocks to buy by analysts, with a price target adjustment by Barclays. The company’s lead candidate, cemsidomide, showed promising Phase 1 data for multiple myeloma, achieving a 53% overall response rate.

In Q3 2025, C4 Therapeutics’ cemsidomide demonstrated a best-in-class profile in Phase 1 trials for multiple myeloma. The company plans to initiate Phase 2 trials in early 2026 and collaborate with Pfizer for further studies. C4T is also leveraging its TORPEDO platform for non-oncology indications.

C4 Therapeutics Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates to degrade disease-causing proteins. The company’s innovative approach has shown promise in clinical trials for multiple myeloma treatment.

While C4 Therapeutics shows investment potential, some believe other AI stocks offer greater upside with less risk. For those interested in AI stocks with significant growth potential, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?